Listen to the losses call carefully.
Europe must be addressed. JJ said before that he was looking for a *sales* partner. Even a couple quarters ago, nobody would invest in a facility to make the drug under license when we have so little cash going forward. Now, we are way too close to the "one year cash" mark that makes us "not a going concern".
So, there isn't enough cash to build a facility in Europe and not enough stability to get even a sales partner. He has to address this somehow.
There was one company interested in the sales partnership together with the $300M dilution if it was "priced right", but I gather they rejected $2/share and it will certainly be harder to get that as time goes on. What's a fat man to do?
Europe must be addressed. JJ said before that he was looking for a *sales* partner. Even a couple quarters ago, nobody would invest in a facility to make the drug under license when we have so little cash going forward. Now, we are way too close to the "one year cash" mark that makes us "not a going concern".
So, there isn't enough cash to build a facility in Europe and not enough stability to get even a sales partner. He has to address this somehow.
There was one company interested in the sales partnership together with the $300M dilution if it was "priced right", but I gather they rejected $2/share and it will certainly be harder to get that as time goes on. What's a fat man to do?